These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22436039)

  • 1. Commentary: is CRP ready for use to indicate response or remission with infliximab in Crohn's?
    Card T
    Aliment Pharmacol Ther; 2012 Apr; 35(8):960-1; discussion 961-2. PubMed ID: 22436039
    [No Abstract]   [Full Text] [Related]  

  • 2. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W; Wang Y; Oddens BJ; Link R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 5. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
    Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
    Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
    [No Abstract]   [Full Text] [Related]  

  • 6. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
    Willot S; Vermeire S; Ohresser M; Rutgeerts P; Paintaud G; Belaiche J; De Vos M; Van Gossum A; Franchimont D; Colombel JF; Watier H; Louis E
    Pharmacogenet Genomics; 2006 Jan; 16(1):37-42. PubMed ID: 16344720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab in Crohn's disease.
    Rodrigo Saéz L
    Rev Esp Enferm Dig; 2004 Jun; 96(6):359-63; 364-8. PubMed ID: 15230665
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
    Magro F; Rodrigues-Pinto E; Santos-Antunes J; Vilas-Boas F; Lopes S; Nunes A; Camila-Dias C; Macedo G
    J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy and predictors of response to infliximab in Korean patients with Crohn's disease].
    Lee KM
    Korean J Gastroenterol; 2013 May; 61(5):241-5. PubMed ID: 23905245
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab and Crohn's QOL.
    Wicks AC; Thomas C; Curran R; Mayberry JF
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1831-2. PubMed ID: 12269979
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of oesophageal Crohn's disease with infliximab.
    Theodoropoulou A; Koutroubakis IE; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2004 Apr; 16(4):431-2. PubMed ID: 15028980
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of infliximab in South-east Asian children with severe Crohn's disease.
    Lee WS
    Pediatr Int; 2004 Apr; 46(2):198-201. PubMed ID: 15056252
    [No Abstract]   [Full Text] [Related]  

  • 16. Does smoking decrease the response to infliximab in patients with Crohn's disease?
    Parsi MA
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S18-9. PubMed ID: 18816687
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful use of infliximab for perianal Crohn's disease in pregnancy.
    Chaparro M; Gisbert JP
    Inflamm Bowel Dis; 2011 Mar; 17(3):868-9. PubMed ID: 20564533
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence for the clinical use of infliximab in Crohn's disease.
    Turner SM; Probert CS
    Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab for Crohn's disease: more questions than answers.
    Freeman HJ
    Can J Gastroenterol; 2001 Jun; 15(6):360-2. PubMed ID: 11429663
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.